Thursday, April 11, 2019, Anaheim, California, 6:00 PM – 8:00 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A 6-Part CNE Symposia Series Held During the ONS 44th Annual Congress

PART 5 — Breast Cancer

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room:
Grand Ballroom E-K (Lobby Level)
5:30 PM – 6:00 PM
Registration and Dinner Buffet

6:00 PM – 8:00 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Elizabeth O’Reilly, RN, NP, MSN, MPH
Nurse Practitioner, Breast Oncology
Susan F Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Boston, Massachusetts

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical
Trials Education
University of California, San Francisco
Medical Center
UCSF Helen Diller Family Comprehensive
Cancer Center
San Francisco, California

Gretchen Santos, RN, MSN, FNP-BC
University of California, San Francisco
Medical Center
UCSF Helen Diller Family Comprehensive
Cancer Center
San Francisco, California

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by Genentech, Lilly, Merck, Novartis and Puma Biotechnology Inc during the Oncology Nursing Society’s (ONS) 44th Annual Congress, April 11-14, 2019 in Anaheim, California. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
5:30 PM – 6:00 PM — Registration and Dinner Buffet
6:00 PM – 8:00 PM — Educational Program

Module 1: Evolving Paradigms in the Management of ER-Positive Metastatic Breast Cancer (mBC)


  • Clinical and biologic factors under consideration when designing a therapeutic plan for patients with ER-positive mBC: prior treatment exposure, disease-free interval, age, menopausal status, symptomatology, location and extent of metastases
  • Published research data with and current clinical role of CDK4/6 inhibitors in premenopausal, postmenopausal and elderly patients with ER-positive mBC
  • Similarities and differences among commercially available CDK4/6 inhibitors; incidence, monitoring and treatment of commonly occurring toxicities in patients receiving CDK4/6 inhibitors
  • Optimal management of disease progressing on CDK4/6 inhibitors in combination with hormonal therapy
  • Incidence and clinical implications of PI3 kinase mutations in patients with progressive ER-positive mBC; available efficacy and safety findings with the alpha-specific PI3K inhibitor alpelisib with fulvestrant for postmenopausal patients with ER-positive, HER2-negative advanced BC with PIK3CA mutations and disease progression on or after an aromatase inhibitor with or without a CDK4/6 inhibitor
  • Incorporating everolimus into the treatment algorithm for patients with ER-positive mBC
  • Counseling patients receiving oral therapies regarding adherence

Module 2: New Agents and Emerging Strategies for HER2-Negative mBC


  • Clinical trial results supporting the recent FDA approval of atezolizumab in combination with nab paclitaxel for unresectable locally advanced or metastatic PD-L1-positive triple-negative BC
  • Mechanisms underlying immune-related adverse events associated with anti-PD-1/PD-L1 antibody therapy
  • Optimal monitoring of patients receiving anti-PD-1/PD-L1 antibodies for the presence of immune-mediated adverse events; supportive care protocols and indications for withholding or permanently discontinuing therapy
  • Ongoing Phase III studies evaluating anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for localized, locally advanced and metastatic breast cancer
  • Indications for BRCA mutation testing in patients with BC; implications of a BRCA1/2 germline mutation for prognosis and current therapeutic selection
  • Data sets supporting the FDA approvals of olaparib and talazoparib for patients with mBC and a BRCA germline mutation
  • Recognition and management of common PARP inhibitor-associated adverse events

Module 3: Recently Approved and Investigational Approaches for Localized and Advanced HER2-Positive Disease


  • Indications for neoadjuvant systemic therapy and selection of optimal approach
  • FDA approval of and patient selection for pertuzumab as a component of adjuvant treatment; indications for the use of adjuvant pertuzumab in patients receiving it as a component of neoadjuvant therapy
  • Key efficacy and safety results with adjuvant T-DM1 for patients with HER2-positive primary BC with residual disease after preoperative therapy
  • Patient selection for postadjuvant neratinib and factors guiding its use in clinical practice
  • Common side effects observed with neratinib; potential strategies to mitigate associated gastrointestinal toxicity
  • Clinical factors (eg, age, performance status, sites of disease, symptomatology, prior adjuvant therapy) influencing the sequencing of anti-HER2 agents in the metastatic setting; integration of T-DM1 into the treatment algorithm
  • Efficacy and safety of neratinib/capecitabine for patients with HER2-positive BC and brain metastases
  • Mechanisms of action of, early activity and safety data with and ongoing evaluation of novel HER2-directed therapies (eg, tucatinib, margetuximab, trastuzumab deruxtecan)

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer (BC).

Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:

  • Apply existing and emerging research data to the diagnostic, therapeutic and supportive care of patients with early and advanced BC.
  • Implement a long-term clinical plan for the management of early and advanced HER2-positive BC, incorporating existing and investigational targeted treatments.
  • Recognize the FDA-endorsed indications for the commercially available CDK4/6 inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with ER-positive metastatic BC (mBC).
  • Develop an understanding of the frequency and potential biologic implications of PIK3CA mutations in patients with ER-positive mBC previously treated with endocrine therapy, and appreciate published research data documenting the efficacy and safety of novel agents targeting this abnormality.
  • Develop a plan to manage the side effects associated with available and recently approved systemic therapies to support quality of life and continuation of treatment.
  • Appreciate the biologic rationale for and available data with novel immunotherapeutic approaches to facilitate their introduction into clinical practice for appropriate patients with mBC.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 2 contact hours is provided by RTP.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CME/CNE planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Genentech, Lilly, Merck, Novartis and Puma Biotechnology Inc.

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room: 
Grand Ballroom E-K (Lobby Level)

The Anaheim Marriott is the headquarters hotel for the 2019 ONS Congress and is conveniently located near the Anaheim Convention Center (0.2 miles).


Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 5 — Breast Cancer. Onsite registration will be open starting at 5:30 PM on Thursday, April 11, 2019. If you are interested in standing by for seating (day of the program), please visit our onsite registration desk located outside the Grand Ballroom (Lobby Level) at the Anaheim Marriott hotel (700 West Convention Way, Anaheim, CA 92802). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis prioritized for oncology nurses treating patients. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at or call (800) 233-6153.